HER2-positive Metastatic Breast Cancer in Kazakhstan
← catalyst calendarNCT07593196 · readout in 41 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Not yet recruiting
Study type
Observational
Enrollment
240estimated
Sites
12
Country
Kazakhstan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-19 | estimated | When the study began enrolling |
| Primary completion | 2026-09-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-01-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Breast Cancer
Primary outcome
what the primary-completion date above is the date OF(1) To assess median PFS and PFS rate in patients with HER2-positive mBC receiving anti-HER2 therapy (except for trastuzumab deruxtecan) in routine practice in Kazakhstan
measured up to 2 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed